<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Uil, C.A. den</title>
    <link>http://repub.eur.nl/res/aut/16807/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Relation between preoperative and intraoperative new wall motion abnormalities in vascular surgery patients: A transesophageal echocardiographic study (Article)</title>
      <link>http://repub.eur.nl/res/pub/19238/</link>
      <pubDate>2010-03-01T00:00:00Z</pubDate>
      <description>Background: Coronary revascularization of the suspected culprit coronary lesion assessed by preoperative stress testing is not associated with improved outcome in vascular surgery patients. Methods: Fifty-four major vascular surgery patients underwent preoperative dobutamine echocardiography and intraoperative transesophageal echocardiography. The locations of left ventricular rest wall motion abnormalities and new wall motion abnormalities (NWMAs) were scored using a seven-wall model. During 30-day follow-up, postoperative cardiac troponin release, myocardial infarction, and cardiac death were noted. Results: Rest wall motion abnormalities were noted by dobutamine echocardiography in 17 patients (31%), and transesophageal echocardiography was noted in 16 (30%). NWMAs were induced during dobutamine echocardiography in 17 patients (31%), whereas NWMAs were observed by transesophageal echocardiography in 23 (43%), κ value = 0.65. Although preoperative and intraoperative rest wall motion abnormalities showed an excellent agreement for the location (κ value = 0.92), the agreement for preoperative and intraoperative NWMAs in different locations was poor (κ value = 0.26-0.44). The composite cardiac endpoint occurred in 14 patients (26%). Conclusions: There was a poor correlation between the locations of preoperatively assessed stress-induced NWMAs by dobutamine echocardiography and those observed intraoperatively using transesophageal echocardiography. However, the composite endpoint of outcome was met more frequently in relation with intraoperative NWMAs.</description>
    </item> <item>
      <title>Percutaneous assist devices vs. intra-aortic balloon pump for cardiogenic shock: Evidence under construction vs. expert opinion: Reply (Article)</title>
      <link>http://repub.eur.nl/res/pub/19296/</link>
      <pubDate>2010-02-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>The microcirculation in severe heart failure and cardiogenic shock (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/22654/</link>
      <pubDate>2009-11-25T00:00:00Z</pubDate>
      <description>This thesis reports characteristics of the microcirculation in cardiogenic shock, as well as approaches to influence microvascular blood flow.</description>
    </item> <item>
      <title>Perioperative Blood Glucose Monitoring and Control in Major Vascular Surgery Patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/27002/</link>
      <pubDate>2009-11-01T00:00:00Z</pubDate>
      <description>Diabetes mellitus (DM) is an independent predictor for morbidity and mortality in the general population, which is even more apparent in patients with concomitant cardiovascular risk factors. As the prevalence of DM is increasing, with an ageing general population, it is expected that the number of diabetic patients requiring surgical interventions will increase. Perioperative hyperglycaemia, without known DM, has been identified as a predictor for morbidity and mortality in patients undergoing surgery. Moreover, early studies showed that intensive blood-glucose-lowering therapy reduced both morbidity and mortality among patients admitted to the postoperative intensive care unit (ICU). However, later studies have doubted the benefit of intensive glucose control in medical-surgical ICU patients. This article aims to comprehensively review the evidence on the use of perioperative intensive glucose control, and to provide recommendations for current clinical practice. A systematic review was performed of the literature on perioperative intensive glucose control. Based on this literature review, we observed that intensive glucose control in the perioperative period has no clear benefit on short-term mortality. Intensive glucose control may even have a net harmful effect in selected patients. In addition, concerns on the external validity of some studies are important barriers for widespread recommendation of intensive glucose control in the perioperative setting. We propose that guidelines recommending intensive glucose control should be re-evaluated. In addition, moderate tight glucose control should currently be regarded as the safest and most efficient approach to patients undergoing major vascular surgery. </description>
    </item> <item>
      <title>Mechanical Circulatory Support Devices Improve Tissue Perfusion in Patients With End-Stage Heart Failure or Cardiogenic Shock (Article)</title>
      <link>http://repub.eur.nl/res/pub/24377/</link>
      <pubDate>2009-09-01T00:00:00Z</pubDate>
      <description>Objectives: This study evaluated the effects of mechanical circulatory support (MCS) on sub-lingual microcirculation as a surrogate for splanchnic microvascular perfusion. Methods: Between May 2008 and April 2009, 10 consecutive patients received an MCS device or extracorporeal membrane oxygenation for end-stage chronic heart failure (n = 6) or cardiogenic shock (n = 4). Microcirculation was investigated using a hand-held Sidestream Dark Field imaging device. Perfused capillary density (PCD) and capillary red blood cell velocity (cRBCv) were assessed before device implantation (T0), immediately after implantation (T1), and 1 day after implantation (T2). Results: Median patient age was 45 years (interquartile range [IQR] 38-52 years) and 70% were men. MCS significantly decreased pulmonary capillary wedge pressure (p = 0.04). Median cardiac power index increased (0.29 [IQR, 0.21-0.34] W/m2at T0 vs 0.48 [IQR, 0.39-0.54] W/m2at T1, p = 0.005) as well as median central venous oxygen saturation (54% [IQR, 46%-61%] at T0 vs 78% [IQR, 67%-85%] at T1, p = 0.007). There was a 3-fold increase in tissue perfusion index (sub-lingual PCD × cRBCv) during mechanical circulatory support (573 [IQR, 407-693] at T0 vs 1909 [IQR, 1771-2835] at T1, p = 0.005). Microcirculatory parameters remained improved at T2. Conclusion: Mechanical circulatory support for severe heart failure is associated with a consistent, significant, and sustained improvement in tissue perfusion, as measured at the bedside by a 2-dimensional microcirculation imaging technique. </description>
    </item> <item>
      <title>Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: A meta-analysis of controlled trials (Article)</title>
      <link>http://repub.eur.nl/res/pub/24653/</link>
      <pubDate>2009-09-01T00:00:00Z</pubDate>
      <description>Aims Studies have compared safety and efficacy of percutaneous left ventricular assist devices (LVADs) with intra-aortic balloon pump (IABP) counterpulsation in patients with cardiogenic shock. We performed a meta-analysis of controlled trials to evaluate potential benefits of percutaneous LVAD on haemodynamics and 30-day survival.Methods and resultsTwo independent investigators searched Medline, Embase, and Cochrane Central Register of Controlled Trials for all controlled trials using percutaneous LVAD in patients with cardiogenic shock, where after data were extracted using standardized forms. Weighted mean differences (MDs) were calculated for cardiac index (CI), mean arterial pressure (MAP), and pulmonary capillary wedge pressure (PCWP). Relative risks (RRs) were calculated for 30-day mortality, leg ischaemia, bleeding, and sepsis. In main analysis, trials were combined using inverse-variance random effects approach. Two trials evaluated the TandemHeart and a recent trial used the Impella device. After device implantation, percutaneous LVAD patients had higher CI (MD 0.35 L/min/m2, 95 CI 0.09-0.61), higher MAP (MD 12.8 mmHg, 95 CI 3.6-22.0), and lower PCWP (MD -5.3 mm Hg, 95 CI -9.4 to -1.2) compared with IABP patients. Similar 30-day mortality (RR 1.06, 95 CI 0.68-1.66) was observed using percutaneous LVAD compared with IABP. No significant difference was observed in incidence of leg ischaemia (RR 2.59, 95 CI 0.75-8.97) in percutaneous LVAD patients compared with IABP patients. Bleeding (RR 2.35, 95 CI 1.40-3.93) was significantly more observed in TandemHeart patients compared with patients treated with IABP. ConclusionAlthough percutaneous LVAD provides superior haemodynamic support in patients with cardiogenic shock compared with IABP, the use of these more powerful devices did not improve early survival. These results do not yet support percutaneous LVAD as first-choice approach in the mechanical management of cardiogenic shock.</description>
    </item> <item>
      <title>Usefulness of Intra-Aortic Balloon Pump Counterpulsation in Patients With Cardiogenic Shock from Acute Myocardial Infarction (Article)</title>
      <link>http://repub.eur.nl/res/pub/24262/</link>
      <pubDate>2009-08-01T00:00:00Z</pubDate>
      <description>Although intra-aortic balloon pump (IABP) counterpulsation is increasingly being used for the treatment of patients with cardiogenic shock from acute myocardial infarction, data on the long-term outcomes are lacking. The aim of the present study was to evaluate the 30-day and long-term mortality and to identify predictors for 30-day and long-term all-cause mortality of patients with acute myocardial infarction complicated by cardiogenic shock who were treated with IABP. From January 1990 to June 2004, 300 consecutive patients treated with IABP were included. The mean age of the study population was 61 ± 11 years, and 79% of the patients were men. The survival rate until IABP removal after successful hemodynamic stabilization was 70% (n = 211). The overall cumulative 30-day survival rate was 58%. The 30-day mortality rate decreased over time from 52% in 1990 to 1994 to 36% in 2000 to 2004 (p for trend &lt;0.05). Follow-up ranged from 0 to 15 years. In patients who survived until IABP removal, the cumulative 1-, 5-, and 10-year survival rate was 69%, 58%, and 36%, respectively. The adjusted predictors of long-term mortality were arrhythmias during the intensive cardiac care unit stay (hazard ratio [HR] 1.8, 95% confidence interval [CI] 1.2 to 2.9) and renal failure during the intensive cardiac care unit stay (HR 2.5, 95% CI 1.3 to 5.1). After adjustment, treatment with primary percutaneous coronary intervention (HR 0.5, 95% CI 0.3 to 0.9) and coronary artery bypass grafting (HR 0.4, 95% CI 0.2 to 0.8) were associated with lower long-term mortality. In conclusion, in patients with acute myocardial infarction complicated by cardiogenic shock treated with IABP, the 30-day survival improved with time and an encouraging number of patients survived in the long term. </description>
    </item> <item>
      <title>Prognosis of patients undergoing cardiac surgery and treated with intra-aortic balloon pump counterpulsation prior to surgery: A long-term follow-up study (Article)</title>
      <link>http://repub.eur.nl/res/pub/25395/</link>
      <pubDate>2009-08-01T00:00:00Z</pubDate>
      <description>The aim of this study was to evaluate short- and long-term outcome in patients undergoing coronary artery bypass grafting (CABG), who received an intra-aortic balloon pump (IABP) prior to surgery. Between January 1990 and June 2004, all patients (n=154) who received an IABP prior to on-pump CABG in our center were included. Patients received the IABP for vital indications (i.e. either unstable angina refractory to medical therapy or cardiogenic shock; group 1: n=99) or for prophylactic reasons (group 2: n=55). A Cox proportional hazards model was used to identify predictors of long-term all-cause mortality. Compared with the EuroSCORE predictive model, observed 30-day mortality in group 1 (15.2%) was slightly higher than predicted (10.3%). A decrease in 30-day mortality occurred in group 2 (median predicted mortality was 7.2% and observed was 0%). Cumulative 1-, 5-, and 6-year survival was 82.8±3.8%, 70.1±4.9%, and 67.3±5.1% for group 1 vs. 98.2±1.8%, 84.0±5.6% and 84.0±5.6% for group 2 (Log-rank: P=0.02). Logistic EuroSCORE (HR 1.03 w1.01-1.05x, Ps0.007) was an independent predictor of long-term all-cause mortality.</description>
    </item> <item>
      <title>Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure (Article)</title>
      <link>http://repub.eur.nl/res/pub/26942/</link>
      <pubDate>2009-07-29T00:00:00Z</pubDate>
      <description>Introduction: Microcirculatory abnormalities are frequently observed in patients with severe heart failure and correlate to worse outcomes. We tested the hypothesis that nitroglycerin dose-dependently improves perfusion in severe heart failure and that this could be monitored by measuring central-peripheral temperature gradient and with Sidestream Dark Field imaging of the sublingual mucosa. Methods: A dose-response study was performed in 17 patients with cardiogenic shock (n = 9) or end-stage chronic heart failure (n = 8) admitted to Erasmus University Medical Center. We did hemodynamic measurements at baseline and during increasing infusion rates of nitroglycerin (up to a maximum dose of 133 μg min-1). As parameters of tissue perfusion, we measured central-peripheral temperature gradient (delta-T) and sublingual perfused capillary density (PCD). Results: Nitroglycerin dose-dependently decreased mean arterial pressure (p &lt; 0.001) and cardiac filling pressures (both central venous pressure (CVP) and pulmonary capillary wedge pressure: p &lt; 0.001). It increased cardiac index (p = 0.01). Nitroglycerin decreased delta-T (p &lt; 0.001) and increased sublingual PCD (p &lt; 0.001). Significant changes in delta-T and PCD occurred earlier, i.e., at a lower doses of NTG, than changes in global hemodynamics. Macrohemodynamic and microcirculatory responses to nitroglycerin infusion were consistent in patients with either cardiogenic shock or end-stage chronic heart failure. Changes in microcirculatory parameters occurred independently of changes in cardiac index. Conclusions: Nitroglycerin dose-dependently increases tissue perfusion in patients with severe heart failure, as observed by a decrease in central-peripheral temperature gradient and an increase in sublingual perfused capillary density. </description>
    </item> <item>
      <title>Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure (Article)</title>
      <link>http://repub.eur.nl/res/pub/24656/</link>
      <pubDate>2009-04-01T00:00:00Z</pubDate>
      <description>AimsImpaired tissue perfusion is often observed in patients with acute heart failure. We tested whether low-dose nitroglycerin (NTG) improves microcirculatory perfusion in patients admitted for acute heart failure.Methods and resultsIn 20 acute heart failure patients, NTG was given as intravenous infusion at a fixed dose of 33 g/min. Using Sidestream Dark Field (SDF) imaging, sublingual microvascular perfusion was evaluated before (T0, average of two baseline measurements) and 15 min after initiation of NTG (T1). In a subgroup of seven patients, SDF measurements were repeated after NTG had been stopped for 20 min. Capillaries were defined as microvessels with a diameter of &lt;20 m. Perfused capillary density (PCD) was determined as the parameter of tissue perfusion. Values are expressed as median and interquartile range (P25; P75). The median age of the subjects was 60 (52; 73) years, and 65 were male. Patients were stable before starting NTG. Nitroglycerin decreased central venous pressure [17 (13; 19) mmHg at T0 vs. 16 (13; 17) mmHg at T1, P = 0.03] and pulmonary capillary wedge pressure [23 (18; 31) mmHg at T0 vs. 19 (16; 25) mmHg at T1, P = 0.03]. It increased PCD [10.7 (9.9; 12.5) mm mm-2at T0 vs. 12.4 (11.4; 13.6) mm mm-2at T1, P = 0.01]. After cessation of NTG, PCD returned to baseline values (P = 0.04).ConclusionLow-dose NTG significantly reduces cardiac filling pressures and improves microvascular perfusion in patients admitted for acute heart failure.</description>
    </item> <item>
      <title>The renin-angiotensin-aldosterone system: Approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/27217/</link>
      <pubDate>2009-03-01T00:00:00Z</pubDate>
      <description>Drugs that modulate the renin-angiotensin-aldosterone system (RAAS) play an important role in modern cardiovascular prevention strategies. Inhibitors of the RAAS, in particular angiotensin-converting enzyme (ACE) inhibitors, have been proven to be beneficial in specific patient groups, including patients with hypertension, heart failure, diabetes mellitus and stable coronary artery disease. Although clinical trials demonstrated a rather consistent beneficial effect of ACE inhibitors across groups of patients based on clinical characteristics, the variability in treatment response on the individual patient level is extensive. Recent publications suggest that genetic polymorphisms in the RAAS are related to cardiovascular risk. Genetic variability also seems associated with the response to ACE inhibitor therapy, and can probably be used to tailor treatment. This review discusses several approaches to guide ACE inhibitor therapy in patients with coronary artery disease. In addition, the potential impact of pharmacogenetics regarding this particular topic is highlighted. Copyright </description>
    </item> <item>
      <title>Intractable supraventricular tachycardia as first presentation of thoracic aortic dissection. Case report (Article)</title>
      <link>http://repub.eur.nl/res/pub/27008/</link>
      <pubDate>2009-01-26T00:00:00Z</pubDate>
      <description>A patient presented with palpitations at the emergency department 3 days after a percutaneous coronary intervention complicated by dissection of the left anterior descending and circumflex coronary arteries. Physical examination revealed a high pulse rate and low blood pressure and the electrocardiogram demonstrated atrioventricular nodal re-entry tachycardia. This arrhythmia was eventually terminated by electrical cardioversion. Echocardiography demonstrated moderate aortic regurgitation and subsequent computed tomography showed a large Stanford type A aortic dissection. The patient was successfully operated and discharged 10 days after surgery. </description>
    </item> <item>
      <title>The Heterogeneity of the Microcirculation in Critical Illness (Article)</title>
      <link>http://repub.eur.nl/res/pub/14508/</link>
      <pubDate>2008-12-01T00:00:00Z</pubDate>
      <description>Microcirculation, a complex and specialized facet of organ architecture, has characteristics that vary according to the function of the tissue it supplies. Bedside technology that can directly observe microcirculation in patients, such as orthogonal polarization spectral imaging and sidestream dark field imaging, has opened the way to investigating this network and its components, especially in critical illness and surgery. These investigations have underscored the central role of microcirculation in perioperative disease states. They have also highlighted variations in the nature of microcirculation, both among organ systems and within specific organs. Supported by experimental studies, current investigations are better defining the nature of microcirculatory alterations in critical illness and how these alterations respond to therapy. This review focuses on studies conducted to date on the microcirculatory beds of critically ill patients. The functional anatomy of microcirculation networks and the role of these networks in the pathogenesis of critical illness are discussed. The morphology of microvascular beds that have been visualized during surgery and intensive care at the bedside are also described, including those of the brain, sublingual region, skin, intestine, and eyes.</description>
    </item> <item>
      <title>Angiotensinogen gene haplotypes in hypertension (Article)</title>
      <link>http://repub.eur.nl/res/pub/29544/</link>
      <pubDate>2008-12-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Microcirculation and multi-organ failure in patients with sepsis (Article)</title>
      <link>http://repub.eur.nl/res/pub/29678/</link>
      <pubDate>2008-09-25T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>The Microcirculation in Health and Critical Disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/28955/</link>
      <pubDate>2008-09-01T00:00:00Z</pubDate>
      <description>The microcirculation is a complex system, which regulates the balance between oxygen demand and supply of parenchymal cells. In addition, the peripheral microcirculation has an important role in regulating the hemodynamics of the human body because it warrants arterial blood pressure as well as venous return to the heart. Novel techniques have made it possible that the microcirculation can be observed directly at the bedside in patients. Currently, research using these new techniques is focusing at the central role of the microcirculation in critical diseases. Experimental studies have demonstrated differences in microvascular alterations between models of septic and hypovolemic shock. In human studies, the microcirculation has most extensively been investigated in septic syndromes and has revealed highly heterogeneous alterations with clear evidence of arteriolar-venular shunting. Until now, the microcirculation in acute heart failure syndromes such as cardiogenic shock has scarcely been investigated. This review concerns the physiologic properties of the microcirculation as well as its role in pathophysiologic states such as sepsis, hypovolemic shock, and acute heart failure. </description>
    </item> <item>
      <title>ACE insertion/deletion polymorphism in sepsis and acute respiratory distress syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/29713/</link>
      <pubDate>2008-09-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Impaired sublingual microvascular perfusion during surgery with cardiopulmonary bypass: A pilot study (Article)</title>
      <link>http://repub.eur.nl/res/pub/29199/</link>
      <pubDate>2008-07-01T00:00:00Z</pubDate>
      <description>Objective: Complications after cardiac surgery may involve multiple organ failure, which carries a high mortality. Development of multiple organ failure may be related to impaired microcirculatory perfusion as a result of systemic inflammation. Microcirculatory blood flow alterations have been associated with impaired outcome. We investigated whether these alterations occurred before, during, and after coronary artery bypass grafting. Methods: We observed 25 consecutive patients who underwent elective coronary artery bypass grafting with cardiopulmonary bypass. The sublingual microcirculation was investigated using side-stream dark-field imaging. Side-stream dark-field imaging was performed before (baseline), during, and after surgery. Microvascular blood flow was estimated with a semiquantitative microvascular flow index in small, medium, and large microvessels. Changes in microvascular flow were tested with Wilcoxon signed rank test. Results: Median microvascular flow index of medium blood vessels decreased after starting cardiopulmonary bypass relative to that after anesthetic induction (2.6, interquartile range 1.6-3.0, vs 3.0, interquartile range 2.8-3.0, P = .02). There was a trend toward decreased microvascular flow index of small and large vessels relative to baseline (P = .08 and P = .05, respectively). Decreases in microvascular flow index occurred irrespective of changes in systemic blood pressure. After each patient's return to the intensive care unit, microvascular flow index increased and normalized in all microvessels. Conclusion: For the first time, sublingual microvascular blood flow alterations have been observed during cardiopulmonary bypass-assisted coronary artery bypass grafting. </description>
    </item> <item>
      <title>Pharmacogenetics of ACE inhibition in stable coronary artery disease: Steps towards tailored drug therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/29532/</link>
      <pubDate>2008-07-01T00:00:00Z</pubDate>
      <description>PURPOSE OF REVIEW: Several trials demonstrated that angiotensin-converting enzyme inhibitors reduce the incidence of cardiovascular events during long-term follow-up in high-risk and low-risk patients. Clinical treatment guidelines propose that angiotensin-converting enzyme inhibitors should be considered in the routine secondary prevention in the broad group of coronary artery disease patients. This review discusses several approaches to guide angiotensin- converting enzyme-inhibition therapy to more specific groups of patients that are most likely to benefit. RECENT FINDINGS: The beneficial effect of angiotensin-converting enzyme inhibition has been shown to be consistent across subgroups in stable coronary artery disease. Still, large interindividual variability in blood pressure response is well documented. It should also be realized that the absolute treatment effects are modest. The efficiency and cost-effectiveness of this prolonged prophylactic treatment would be significantly enhanced if those patients can be distinguished who benefit most. Recently, it was suggested that markers of an activated renin-angiotensin- aldosterone system might be used to guide angiotensin-converting enzyme-inhibition therapy. SUMMARY: At the start of treatment, clinical characteristics are not sufficient to distinguish between patients who will and will not benefit from angiotensin-converting enzyme inhibitors. Although pharmacogenetic research in coronary artery disease is still in a premature stage, it may be expected to provide a useful tool in optimizing and individualizing the management of angiotensin-converting enzyme-inhibitor therapy in coronary artery disease patients. </description>
    </item> <item>
      <title>Does red blood cell transfusion result in a variate microvascular response in sepsis? [4] (Article)</title>
      <link>http://repub.eur.nl/res/pub/35172/</link>
      <pubDate>2007-10-01T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>